Tenax Therapeutics, Inc.

NasdaqCM TENX

Tenax Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -3.15

Tenax Therapeutics, Inc. Price to Earnings Ratio (P/E) is -3.15 on January 14, 2025, a -5,821.76% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Tenax Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.02 on March 25, 2024, which is 99.47% above the current Price to Earnings Ratio (P/E).
Tenax Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -3.24 on January 02, 2025, which is -2.98% below the current Price to Earnings Ratio (P/E).
Tenax Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.60.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: TENX

Tenax Therapeutics, Inc.

CEO	Mr. Christopher T. Giordano
IPO Date	April 4, 1994
Location	United States
Headquarters	ONE Copley Parkway
Employees	5
Sector	Health Care
Industries Pharmaceuticals

Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Key trends

Past 5 years